Herantis: Approval to start phase I study with HER-096 - Redeye

Redeye endorses today’s news that Herantis has received approval to start its phase I study with HER-096 in healthy volunteers. To us, the step back into the clinic has been an important milestone and we like that the timeline continues to be followed. We will discuss the trial further in relation to the H2 report.

Länk till analysen i sin helhet: https://www.redeye.se/research/881600/herantis-approval-to-start-phase-i-study-with-her-096?utm_source=finwire&utm_medium=RSS